Clinical outcome after enteroscopy for small bowel angioectasia bleeding: A Korean Associateion for the Study of Intestinal Disease (KASID) multiceter study

Small Intestine Research Group of the Korean Association for the Study of Intestinal Disease (KASID)

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background and Aims: Angioectasias are the most common sources of bleeding in the small bowel. They can be treated using balloon-assisted enteroscopy (BAE). This study aimed to identify the rebleeding rate and associated factors after BAE in patients with small bowel angioectasia bleeding. Methods: We retrospectively analyzed the records of patients with bleeding due to small bowel vascular lesion in a multicenter enteroscopy database including 1108 BAEs. Finally, in rebleeding analysis, we analyzed 66 patients with angioectasia on the basis of the Yano-Yamamoto classification. Patients who had undergone endotherapy (ET) were divided into ET (n = 45) and non-ET (n = 21) groups. Rebleeding was defined as evidence of bleeding at least 30 days after BAE. Results: Fifty-three patients (80.4%) underwent only one-side enteroscopy. The most common ET was argon plasma coagulation (87.2%). During a mean follow-up duration of 24.5 months, ET and non-ET groups had rebleeding rates of 15.6% and 38.1% (P = 0.059), respectively. Median rebleeding time of ET and non-ET groups was 32.5 and 62 months, respectively. Liver cirrhosis (LC), low platelet count (< 105/μL), and transfusions were the rebleeding-associated factors in the univariate analysis. In the multivariate analysis, the presence of LC (HR 4.064, 95% CI 1.098–15.045; P = 0.036) was the only independent rebleeding-associated risk factor. Conclusions: ET using BAE did not significantly affect the rebleeding rate in patients with small bowel angioectasia bleeding. An independent rebleeding risk factor was the presence of LC. Regardless of ET, careful long-term follow-up may be needed, especially in LC patients with small bowel angioectasia bleeding.

Original languageEnglish
Pages (from-to)388-394
Number of pages7
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume32
Issue number2
DOIs
Publication statusPublished - 2017 Feb 1

Fingerprint

Intestinal Diseases
Hemorrhage
Liver Cirrhosis
Argon Plasma Coagulation
Platelet Count
Blood Vessels
Multivariate Analysis
Databases
Balloon Enteroscopy

Keywords

  • balloon-assisted enteroscopy
  • endotherapy
  • obscure gastrointestinal bleeding
  • rebleeding

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Clinical outcome after enteroscopy for small bowel angioectasia bleeding : A Korean Associateion for the Study of Intestinal Disease (KASID) multiceter study. / Small Intestine Research Group of the Korean Association for the Study of Intestinal Disease (KASID).

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 32, No. 2, 01.02.2017, p. 388-394.

Research output: Contribution to journalArticle

Small Intestine Research Group of the Korean Association for the Study of Intestinal Disease (KASID). / Clinical outcome after enteroscopy for small bowel angioectasia bleeding : A Korean Associateion for the Study of Intestinal Disease (KASID) multiceter study. In: Journal of Gastroenterology and Hepatology (Australia). 2017 ; Vol. 32, No. 2. pp. 388-394.
@article{ad70d09d3bee4e1fbbdb4fffe955c62e,
title = "Clinical outcome after enteroscopy for small bowel angioectasia bleeding: A Korean Associateion for the Study of Intestinal Disease (KASID) multiceter study",
abstract = "Background and Aims: Angioectasias are the most common sources of bleeding in the small bowel. They can be treated using balloon-assisted enteroscopy (BAE). This study aimed to identify the rebleeding rate and associated factors after BAE in patients with small bowel angioectasia bleeding. Methods: We retrospectively analyzed the records of patients with bleeding due to small bowel vascular lesion in a multicenter enteroscopy database including 1108 BAEs. Finally, in rebleeding analysis, we analyzed 66 patients with angioectasia on the basis of the Yano-Yamamoto classification. Patients who had undergone endotherapy (ET) were divided into ET (n = 45) and non-ET (n = 21) groups. Rebleeding was defined as evidence of bleeding at least 30 days after BAE. Results: Fifty-three patients (80.4{\%}) underwent only one-side enteroscopy. The most common ET was argon plasma coagulation (87.2{\%}). During a mean follow-up duration of 24.5 months, ET and non-ET groups had rebleeding rates of 15.6{\%} and 38.1{\%} (P = 0.059), respectively. Median rebleeding time of ET and non-ET groups was 32.5 and 62 months, respectively. Liver cirrhosis (LC), low platelet count (< 105/μL), and transfusions were the rebleeding-associated factors in the univariate analysis. In the multivariate analysis, the presence of LC (HR 4.064, 95{\%} CI 1.098–15.045; P = 0.036) was the only independent rebleeding-associated risk factor. Conclusions: ET using BAE did not significantly affect the rebleeding rate in patients with small bowel angioectasia bleeding. An independent rebleeding risk factor was the presence of LC. Regardless of ET, careful long-term follow-up may be needed, especially in LC patients with small bowel angioectasia bleeding.",
keywords = "balloon-assisted enteroscopy, endotherapy, obscure gastrointestinal bleeding, rebleeding",
author = "{Small Intestine Research Group of the Korean Association for the Study of Intestinal Disease (KASID)} and Jeon, {Seong Ran} and Byeon, {Jeong Sik} and Jang, {Hyun Joo} and Park, {Soo Jung} and Im, {Jong Pil} and Kim, {Eun Ran} and Koo, {Ja Seol} and Ko, {Bong Min} and Chang, {Dong Kyung} and Kim, {Jin Oh} and Park, {Su Yeon}",
year = "2017",
month = "2",
day = "1",
doi = "10.1111/jgh.13479",
language = "English",
volume = "32",
pages = "388--394",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Clinical outcome after enteroscopy for small bowel angioectasia bleeding

T2 - A Korean Associateion for the Study of Intestinal Disease (KASID) multiceter study

AU - Small Intestine Research Group of the Korean Association for the Study of Intestinal Disease (KASID)

AU - Jeon, Seong Ran

AU - Byeon, Jeong Sik

AU - Jang, Hyun Joo

AU - Park, Soo Jung

AU - Im, Jong Pil

AU - Kim, Eun Ran

AU - Koo, Ja Seol

AU - Ko, Bong Min

AU - Chang, Dong Kyung

AU - Kim, Jin Oh

AU - Park, Su Yeon

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background and Aims: Angioectasias are the most common sources of bleeding in the small bowel. They can be treated using balloon-assisted enteroscopy (BAE). This study aimed to identify the rebleeding rate and associated factors after BAE in patients with small bowel angioectasia bleeding. Methods: We retrospectively analyzed the records of patients with bleeding due to small bowel vascular lesion in a multicenter enteroscopy database including 1108 BAEs. Finally, in rebleeding analysis, we analyzed 66 patients with angioectasia on the basis of the Yano-Yamamoto classification. Patients who had undergone endotherapy (ET) were divided into ET (n = 45) and non-ET (n = 21) groups. Rebleeding was defined as evidence of bleeding at least 30 days after BAE. Results: Fifty-three patients (80.4%) underwent only one-side enteroscopy. The most common ET was argon plasma coagulation (87.2%). During a mean follow-up duration of 24.5 months, ET and non-ET groups had rebleeding rates of 15.6% and 38.1% (P = 0.059), respectively. Median rebleeding time of ET and non-ET groups was 32.5 and 62 months, respectively. Liver cirrhosis (LC), low platelet count (< 105/μL), and transfusions were the rebleeding-associated factors in the univariate analysis. In the multivariate analysis, the presence of LC (HR 4.064, 95% CI 1.098–15.045; P = 0.036) was the only independent rebleeding-associated risk factor. Conclusions: ET using BAE did not significantly affect the rebleeding rate in patients with small bowel angioectasia bleeding. An independent rebleeding risk factor was the presence of LC. Regardless of ET, careful long-term follow-up may be needed, especially in LC patients with small bowel angioectasia bleeding.

AB - Background and Aims: Angioectasias are the most common sources of bleeding in the small bowel. They can be treated using balloon-assisted enteroscopy (BAE). This study aimed to identify the rebleeding rate and associated factors after BAE in patients with small bowel angioectasia bleeding. Methods: We retrospectively analyzed the records of patients with bleeding due to small bowel vascular lesion in a multicenter enteroscopy database including 1108 BAEs. Finally, in rebleeding analysis, we analyzed 66 patients with angioectasia on the basis of the Yano-Yamamoto classification. Patients who had undergone endotherapy (ET) were divided into ET (n = 45) and non-ET (n = 21) groups. Rebleeding was defined as evidence of bleeding at least 30 days after BAE. Results: Fifty-three patients (80.4%) underwent only one-side enteroscopy. The most common ET was argon plasma coagulation (87.2%). During a mean follow-up duration of 24.5 months, ET and non-ET groups had rebleeding rates of 15.6% and 38.1% (P = 0.059), respectively. Median rebleeding time of ET and non-ET groups was 32.5 and 62 months, respectively. Liver cirrhosis (LC), low platelet count (< 105/μL), and transfusions were the rebleeding-associated factors in the univariate analysis. In the multivariate analysis, the presence of LC (HR 4.064, 95% CI 1.098–15.045; P = 0.036) was the only independent rebleeding-associated risk factor. Conclusions: ET using BAE did not significantly affect the rebleeding rate in patients with small bowel angioectasia bleeding. An independent rebleeding risk factor was the presence of LC. Regardless of ET, careful long-term follow-up may be needed, especially in LC patients with small bowel angioectasia bleeding.

KW - balloon-assisted enteroscopy

KW - endotherapy

KW - obscure gastrointestinal bleeding

KW - rebleeding

UR - http://www.scopus.com/inward/record.url?scp=85013276238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013276238&partnerID=8YFLogxK

U2 - 10.1111/jgh.13479

DO - 10.1111/jgh.13479

M3 - Article

C2 - 27356264

AN - SCOPUS:85013276238

VL - 32

SP - 388

EP - 394

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 2

ER -